secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2026-02-10T23:59:59+00:00
Accession:  0001437749-26-003577
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex gets Australian patent acceptance for Reqorsa+PD-L1; adds trial site
----------------------------------------------------------------------------

- IP Australia issued Notice of Acceptance on Feb 5, 2026 for patent covering Reqorsa + PD-L1 antibodies in cancer.
- Opened additional Acclaim-3 clinical trial site at University of Kentucky; plans more sites to expand enrollment.
- Acclaim-3 Phase 2 expansion targets ~50 patients; interim analysis after 25th patient expected in H2 2026.
- Patent already granted in US and Korea; pending in Europe, Canada, Brazil, China, and Israel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926003577/0001437749-26-003577-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926003577/gnpx20260209_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-003577

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer